|
|
|
|
|
|
| Jeffrey Litwin, M.D. of ERT, a solution provider company at the marcus evans Evolution Summit 2012, on better patient recruitment in clinical trials. |
NEW YORK, Apr 4, 2012 - (ACN Newswire) - "Pharmaceutical companies can have more success in drug development if they recruit enough of the right patients into their clinical trials," says Dr. Jeffrey Litwin, Chief Executive Officer, ERT. More time must be spent on the inclusion and exclusion criteria, so that eligible patients are not unnecessarily excluded, he adds.
From a solution provider company at the upcoming marcus evans Evolution Summit 2012, in Wheeling, Illinois, April 30 - May 2, Litwin offers his expertise into improving patient recruitment, clinical trial success and innovation.
- What could improve the success rate of clinical trials?
Chief Medical Officers (CMOs) have to make sure that protocols are well written, so that the inclusion and exclusion criteria do not eliminate a large number of patients who would otherwise be eligible. Criteria are often copied from another study and new exclusion criteria for that particular drug are added. Some of the exclusions that carry over from one drug to another are inappropriate. What often happens is a study starts and the CMO finds that many people were excluded for an inapplicable reason. Re-writing the protocol ends up being costly and time consuming.
- What is missing in clinical development today?
Companies are not sharing their data. Many are working on similar compounds, when others have already found that they do not work. There are few publications of failed studies. Pharmaceutical companies consider this information as a competitive advantage, but the reality is that the industry is spending billions of dollars on drugs that have proven unsuccessful. Also, if a certain compound has failed, it does not mean that it would not succeed in a better designed study or in a different formulation. At least other scientists would have some data to work from. Large pharmaceutical companies would all benefit by sharing information on their failures as much as their successes.
- What should they focus more of their time on?
Everyone is focused on drug efficacy and labeling. Of course drug approval is based on that data, but drug safety and pharmacovigilance are important to ensure that patients have adequate information on both the benefits and risks of medications. The centralized collection of data would contribute to better safety databases.
- What could CMOs take advantage of today, to enhance or nurture innovation in this field?
They have to look at the big picture, how the drug or drug development program fits into what is currently available in the marketplace and how they can create a marketing or labeling differentiation. What innovation is the drug bringing to the marketplace?
About the Evolution Summit 2012
This unique forum will take place at the Westin Chicago North Shore, Wheeling, Illinois, April 30 - May 2, 2012. Offering much more than any conference, exhibition or trade show, this exclusive meeting will bring together esteemed industry thought leaders and solution providers to a highly focused and interactive networking event. The Summit includes presentations on the future of drug development, developing a culture of safety and maximizing return on investment.
For more information please send an email to info@marcusevanscy.com or visit the event website at www.evolutionsummit.com/JeffreyLitwinInterview
The Pharma Network - marcus evans Summits group delivers peer-to-peer information on strategic matters, professional trends and breakthrough innovations.
LinkedIn: www.linkedin.com/groups?gid=3529112&trk=myg_ugrp_ovr
YouTube: www.youtube.com/user/MarcusEvansPharma
Twitter: www.twitter.com/meSummitsPharma
SlideShare: www.slideshare.net/MarcusEvansPharma
marcus evans group - life sciences / pharma sector portal - http://bit.ly/HEbwqQ
Please note that the Summit is a closed business event and the number of participants strictly limited.
About ERT
ERT (www.ert.com) is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and Contract Research Organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with unrivaled processes and scientific expertise to collect, analyze, and report on clinical data to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is the acknowledged industry leader in centralized cardiac safety and respiratory efficacy services and also provides electronic Patient Reported Outcomes (ePRO) and Outcomes Assessments for multiple modalities across all phases. For more information, please visit www.ert.com.
Contact:
Sarin Kouyoumdjian-Gurunlian
Press Manager,
marcus evans Summits
Tel: +357-22-849313
Email: press@marcusevanscy.com
Topic: Press release summary
Source: marcus evans Summits
Sectors: Science & Research, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| marcus evans Summits |
| Jan 5, 2016 15:31 HKT/SGT |
|
How the Right Interior Design Can Lead to an Unforgettable Hotel Experience |
| Jan 5, 2016 14:53 HKT/SGT |
|
Why Hotels Need to Invest in Technology |
| Jan 5, 2016 14:15 HKT/SGT |
|
Why Defence Organisations Should Reconsider Their Talent Management Approach |
| Oct 23, 2015 03:00 HKT/SGT |
|
How to Distinguish the Right Emerging Markets to Invest in |
| Oct 22, 2015 21:20 HKT/SGT |
|
How to Design a Solid Privacy and Data Protection Programme |
| Oct 22, 2015 21:00 HKT/SGT |
|
The Wellness Model: A Business Strategy to Reduce Healthcare Costs |
| Oct 17, 2015 02:20 HKT/SGT |
|
The Changing Dynamics of the Oil Market |
| Oct 17, 2015 02:10 HKT/SGT |
|
How China's Slowdown Affects Global Investors |
| Oct 17, 2015 02:00 HKT/SGT |
|
How to Use Globalisation as a Marketing Tool |
| Sept 30, 2015 07:30 HKT/SGT |
|
The Need for Holistic Revenue Cycle Management Models |
| More news >> |
 |
|
|
|
